Here, the Investing News Network provides a breakdown of how to invest in cardiovascular disease treatments and what the market outlook looks like.
By Pia Rivera
Reuters reported that Abbott Laboratories (NYSE:ABT) has offered concessions for its $25 billion bid for St. Jude Medical (NYSE:STJ).
As quoted in the article:
The move pushed back the European Commission’s decision on the deal to Nov. 21 from Nov. 9, according to a filing on the EU competition enforcer’s website on
The company warns that built up lithium deposits in their defibrillators’ batteries can cause them to short circuit.
Q BioMed Inc. (OTCQB:QBIO), a biotechnology acceleration company with a glaucoma drug in development through its partner Mannin Research provides this update on the MAN-01 program and its relevance in the glaucoma market.
Johnson & Johnson is warning customers that its Animas OneTouch Ping Insulin pump can be hacked—a cybersecurity vulnerability that could be deadly.
From contact lenses that measure glucose levels to wireless sensors that read them through the skin, blood sugar monitoring is undergoing a major reinvention. But why are medical device companies investing so much into diabetes management specifically?
St. Jude Medical saw its stock fall four percent after Muddy Waters published a report alleging that the medical device manufacturer had serious cyber security issues. Now, St. Jude is striking back with a lawsuit its CEO calls “critical to the entire medical device ecosystem.”
DUBLIN–(BUSINESS WIRE)–Research and Markets has announced the addition of the “Global
Transcatheter Mitral Valve Replacement (TMVR) Market: Size & Forecasts
(2016-2021)” report to their offering.
Currently, the global TMVR market is in early stage, but it is expected
to increase at high growth rates during the forecasted period
(2016-2021). The global TMVR market is supported
BOSTON, June 27, 2016 (GLOBE NEWSWIRE) — Keryx Biopharmaceuticals, Inc. (Nasdaq:KERX), a biopharmaceutical company focused on bringing innovative medicines to people with renal disease, today announced that Douglas Jermasek will join the company as vice president, marketing and strategy, effective July 1, 2016. In this role, he will be responsible
NEW YORK–(BUSINESS WIRE)–Remedy Pharmaceuticals, a privately-held pharmaceutical company focused
on bringing life-saving hospital-based treatment to people affected by
central nervous system (CNS) related edema, today announced that Roger
Ulrich has joined the company’s board of directors.
In 2006 Dr. Ulrich co-founded Calistoga Pharmaceuticals, which was
acquired by Gilead Sciences (NASDAQ:GILD) in 2011 in a transaction
AUSTIN, Texas, June 08, 2016 (GLOBE NEWSWIRE) — XBiotech (NASDAQ:XBIT), the developer of True Human™ therapeutic antibodies, announced today that Trey Benson has joined the company as Commercial Head, effective June 6. Benson has more than two decades of global healthcare experience, with over 16 years of marketing and commercial
CAMBRIDGE, Mass. & NORTH CHICAGO, Ill.–(BUSINESS WIRE)–The Committee for Medicinal Products for Human Use (CHMP) of the
European Medicines Agency (EMA) has adopted a positive opinion
recommending the granting of a marketing authorization for ZINBRYTA™
(daclizumab) intended for the treatment of relapsing forms of multiple
sclerosis (RMS), Biogen
(NASDAQ: BIIB) and AbbVie (NYSE:
ABBV) announced today. ZINBRYTA is
Electrophysiology devices industry is anticipated to grow at a CAGR of over 5.0% and reach over USD 6.18 billion by 2020 owing to growing old age population and frequent cardiac arrhythmias incidents.